Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain?
Endocannabinoids, endogenous lipid ligands of cannabinoid receptors, mediate a variety of effects similar to those of marijuana. Cannabinoid CB(1) receptors are highly abundant in the brain and mediate psychotropic effects, which limits their value as a potential therapeutic target. There is growing evidence for CB(1) receptors in peripheral tissues that modulate a variety of functions, including pain sensitivity and obesity-related hormonal and metabolic abnormalities. In this review we propose that selective targeting of peripheral CB(1) receptors has potential therapeutic value because it would help to minimize addictive, psychoactive effects in the case of CB(1) agonists used as analgesics, or depression and anxiety in the case of CB(1) antagonists used in the management of cardiometabolic risk factors associated with the metabolic syndrome.
Kunos
George
G
Laboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD 20892, USA. gkunos@mail.nih.gov
Osei-Hyiaman
Douglas
D
Bátkai
Sándor
S
Sharkey
Keith A
KA
Makriyannis
Alexandros
A
D000818:Animals; D015195:Drug Design; D006801:Humans; D007249:Inflammation / Q000503:physiopathology / Q000517:prevention & control; D008659:Metabolic Diseases / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D010146:Pain / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors* / Q000502:physiology; D009626:Terminology as Topic
D043884:Receptor, Cannabinoid, CB1